Dextrofemine: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
==Dextrofemine== | |||
[[File:Dextrofemine.svg|Chemical structure of Dextrofemine|thumb|right]] | |||
'''Dextrofemine''' is a synthetic [[opioid analgesic]] that was developed in the mid-20th century. It is a derivative of [[phenazocine]], which is itself a member of the [[benzomorphan]] class of opioids. Dextrofemine was primarily researched for its potential use in pain management, but it never became widely used in clinical practice. | |||
Dextrofemine is | |||
==Chemical Properties== | |||
Dextrofemine is chemically related to other opioids in the benzomorphan family. Its structure is characterized by a complex arrangement of carbon, hydrogen, nitrogen, and oxygen atoms, which contribute to its pharmacological activity. The chemical formula of dextrofemine is C<sub>22</sub>H<sub>29</sub>NO, and it has a molecular weight of approximately 323.48 g/mol. | |||
==Pharmacology== | ==Pharmacology== | ||
Dextrofemine acts | Dextrofemine acts as an agonist at the [[mu-opioid receptor]], which is the primary receptor responsible for the analgesic effects of opioids. By binding to these receptors, dextrofemine can alter the perception of pain and produce feelings of euphoria. However, like other opioids, it also has the potential for abuse and dependence. | ||
===Mechanism of Action=== | |||
The mechanism of action of dextrofemine involves the inhibition of [[neurotransmitter]] release in the central nervous system. This inhibition occurs because the activation of mu-opioid receptors leads to a decrease in the release of [[substance P]] and other neurotransmitters involved in pain transmission. | |||
==Clinical Use== | ==Clinical Use== | ||
Although dextrofemine was investigated for its | Although dextrofemine was investigated for its analgesic properties, it was never marketed or widely used in clinical settings. The development of other opioids with more favorable profiles, such as [[morphine]] and [[oxycodone]], overshadowed the potential use of dextrofemine. | ||
==Side Effects== | ==Side Effects== | ||
As with other opioids, dextrofemine can cause a range of side effects. Common side effects include [[nausea]], [[vomiting]], [[constipation]], and [[drowsiness]]. More serious side effects can include [[respiratory depression]], which is a potentially life-threatening condition. | |||
==Legal Status== | ==Legal Status== | ||
Dextrofemine | Dextrofemine is not approved for medical use in most countries and is not listed as a controlled substance. However, its structural similarity to other opioids means it could be subject to regulation under analog laws in some jurisdictions. | ||
==Related Pages== | ==Related Pages== | ||
* [[Opioid]] | * [[Opioid]] | ||
* [[Analgesic]] | * [[Analgesic]] | ||
* [[Benzomorphan]] | |||
* [[Mu-opioid receptor]] | * [[Mu-opioid receptor]] | ||
[[Category:Opioids]] | [[Category:Opioids]] | ||
[[Category:Analgesics]] | [[Category:Analgesics]] | ||
[[Category: | [[Category:Benzomorphans]] | ||
Latest revision as of 20:26, 5 March 2025
Dextrofemine[edit]
Dextrofemine is a synthetic opioid analgesic that was developed in the mid-20th century. It is a derivative of phenazocine, which is itself a member of the benzomorphan class of opioids. Dextrofemine was primarily researched for its potential use in pain management, but it never became widely used in clinical practice.
Chemical Properties[edit]
Dextrofemine is chemically related to other opioids in the benzomorphan family. Its structure is characterized by a complex arrangement of carbon, hydrogen, nitrogen, and oxygen atoms, which contribute to its pharmacological activity. The chemical formula of dextrofemine is C22H29NO, and it has a molecular weight of approximately 323.48 g/mol.
Pharmacology[edit]
Dextrofemine acts as an agonist at the mu-opioid receptor, which is the primary receptor responsible for the analgesic effects of opioids. By binding to these receptors, dextrofemine can alter the perception of pain and produce feelings of euphoria. However, like other opioids, it also has the potential for abuse and dependence.
Mechanism of Action[edit]
The mechanism of action of dextrofemine involves the inhibition of neurotransmitter release in the central nervous system. This inhibition occurs because the activation of mu-opioid receptors leads to a decrease in the release of substance P and other neurotransmitters involved in pain transmission.
Clinical Use[edit]
Although dextrofemine was investigated for its analgesic properties, it was never marketed or widely used in clinical settings. The development of other opioids with more favorable profiles, such as morphine and oxycodone, overshadowed the potential use of dextrofemine.
Side Effects[edit]
As with other opioids, dextrofemine can cause a range of side effects. Common side effects include nausea, vomiting, constipation, and drowsiness. More serious side effects can include respiratory depression, which is a potentially life-threatening condition.
Legal Status[edit]
Dextrofemine is not approved for medical use in most countries and is not listed as a controlled substance. However, its structural similarity to other opioids means it could be subject to regulation under analog laws in some jurisdictions.
